The Latest in Lymphoma & Plasma Cell Disorders

Lenalidomide maintenance improves MCL survival after ASCT

January 2, 2019

Lymphoma & Plasma Cell Disorders

Frailty-adjusted treatment strategy emerges in myeloma

December 21, 2018

Lymphoma & Plasma Cell Disorders

Checkmate 436: Two-drug combo is ‘promising’ for PMBCL

December 21, 2018

Lymphoma & Plasma Cell Disorders

ECHELON-2: BV-CHP boosts survival in PTCL

December 20, 2018

Lymphoma & Plasma Cell Disorders

MAIA: Daratumumab plus len-dex improves myeloma PFS

December 12, 2018

Lymphoma & Plasma Cell Disorders

Tom Brokaw opens up on surviving multiple myeloma

December 11, 2018

LCAR-B38M CAR T therapy appears durable in myeloma

December 5, 2018

Lymphoma & Plasma Cell Disorders

2018: A banner year for hematology drug approvals

December 5, 2018

Phase 3 study confirms biosimilarity of PF-05280586 with rituximab

December 5, 2018

CLL resistance mechanism to venetoclax identified

December 5, 2018

In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission

December 5, 2018

TOURMALINE-MM3: Ixazomib improves PFS after myeloma transplant

December 2, 2018

Lymphoma & Plasma Cell Disorders

JULIET: CAR T cells go the distance in r/r DLBCL

December 2, 2018

Beat AML trial delivers genomic results in 7 days

December 2, 2018

JULIET: CAR T cells keep trucking against DLBCL

December 2, 2018

Lymphoma & Plasma Cell Disorders